Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now_老虎社区_美港股上老虎

Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now

InvestorPlace2021-08-27

ZOM stock investors won't get excited until the pet health disruptor improves top-line growth Shares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Troytan
·2021-08-27
Hold tight in for roller coaster ride
回复
1
举报
rachellll
·2021-08-27
a
回复
点赞
举报
收起
- rachellll:
  a
  2021-08-27
  回复
  举报
Jggggtjg
·2021-08-27
Like
回复
2
举报
晓MIIN
·2021-08-27
[微笑]
回复
1
举报
Ice1234
·2021-08-27
[强]
回复
点赞
举报
dzgunners95
·2021-08-27
Well done
回复
3
举报
Andersonkana
·2021-08-27
Good news
回复
1
举报
收起
- dzgunners95:
  cool
  2021-08-27
  回复
  举报
IronRoar
·2021-08-27
good
回复
4
举报
收起
- JiaJun87:
  [Cool][Cool][Cool]
  2021-08-27
  回复
  举报
ngng
·2021-08-27
Daily
回复
2
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1144882928?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-08-27 20:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144882928","market":"us","top_or_hot":-1,"title":"Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now","media":"InvestorPlace","content":"<div>\n<p>ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ...</p>\n\n<a href=\"https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/\">网页链接</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRisks Outweigh Rewards of a Move Into Zomedica Stock Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 20:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ...</p>\n\n<a href=\"https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZOM","symbol_name":"Zomedica Pharmaceuticals Corp.","start_time":0,"source_url":"https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/","article_id":"1144882928","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144882928","pubTimestamp":1630068928,"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZOM":"Zomedica Pharmaceuticals Corp."},"translate_title":"现在进入Zomedica股票的风险大于回报","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZOM":0.9},"content_text":"ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ZOM stock has gained an whopping 51.4% on the back of renewed retail trading interest in the stock.\nThe gains come after the shares had lost a near equal amount in the three months ending Aug. 18. Yet despite this week’s pop, weak fundamentals, unimpressive top-line growth and supply-side issues limit the stock’s attractiveness.\nZomedica’s flagship product is a diagnostics platform called Truforma, which enables veterinarians to detect animal pathologies. It essentially streamlines the decision-making process, enabling veterinarians to begin treating patients — primarily dogs and cats — sooner.\nThe innovative platform launched in March this year but so far hasn’t gained as much traction as its shareholders would’ve hoped for. The novelty of the platform cannot be denied, though, and some catalysts could drive growth in the future. However, Zomedica is far from where it should be, and its bullish narrative is hardly convincing at this stage.\nZOM Stock Sees Supply-Side Troubles\nCEO Robert Cohen highlighted the troubles in ramping up the commercial launch of Truforma in the second-quarter update. He associated the supply-side weaknesses with its partners. Its distribution partner,Miller Veterinary Supply was acquired by Patterson Companies recently. The unexpected sale of its key distributor has compelled the company to alter its sales strategy.\nIt announced that it would be transitioning to a direct sales organization. Zomedica “believed have impacted its ability to market our products effectively, we will be accelerating that transition and the building of a direct sales organization.”\nMoreover, Cohen believes that the delays in completing its fT4 and ACTH assays have also impacted Truforma’s performance. He stated that “We expect that market adoption of Truforma will be challenging until our fT4 and ACTH assays are available for commercial release.”\nMaking Little Progress\nOne thing that is unequivocal at this point is Zomedica’s poor financial performance. In the second quarter, it reported just $15,693 in revenues. In the first quarter, its sales were at $14,124; therefore, it hasn’t made much progress. Moreover, it posted a healthy net loss of $4.7 million in the quarter, $700,000 more than the first quarter.\nPerhaps a bright spot of its financials is its strong cash position. Its cash balance was at $276 million, which has a lot to do with the sale of over 91 million shares this year. Hence, the increase in its cash till came at a heavy price to its shareholders.\nFrom a business standpoint, there are some positive developments which you should probably keep an eye on.\nIt implemented a program that allows customers to receive Truforma instruments if they purchase assay cartridges. Additionally, the company has signed 41 placement agreements and installed 25 Truforma systems under this program. This move could prove to be instrumental for the company in expanding its product lineup.\nZomedica must continue to add value for its customer base to ramp up top-line growth.\nFinal Word On ZOM Stock\nIt’s been quite an eventful year for Zomedica and ZOM stock. After skyrocketing earlier in the year, ZOM stock has come crashing down, as its underlying business has failed to impress investors. Zomedica has failed to ramp up sales of its Truforma platform, raising concerns about the product’s long-term growth runway.\nIt does have some exciting developments on the cards, and the transition to a direct sales model pays dividends down the line. However, the transitory phase should take long before it proves fruitful for the manufacturer of the diagnostic. Moreover, the direct sales strategy could also backfire, requiring it to reestablish relationships with the original distributor or pursue new ones.\nZomedica has a lot to prove at this stage before investors can consider ZOM stock as an attractive investment.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":819504977,"gmtCreate":1630075392699,"gmtModify":1704955629731,"author":{"id":"3571482048865852","authorId":"3571482048865852","name":"Troytan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3571482048865852","authorIdStr":"3571482048865852"},"htmlText":"Hold tight in for&nbsp;roller&nbsp;coaster ride&nbsp;","listText":"Hold tight in for&nbsp;roller&nbsp;coaster ride&nbsp;","text":"Hold tight in for roller coaster ride","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/819504977","repostId":1144882928,"repostType":4,"repost":{"id":"1144882928","pubTimestamp":1630068928,"share":"https://www.laohu8.com/m/news/1144882928?lang=&edition=full","pubTime":"2021-08-27 20:55","market":"us","language":"en","title":"Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1144882928","media":"InvestorPlace","summary":"ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares","content":"<p>ZOM stock investors won't get excited until the pet health disruptor improves top-line growth</p>\n<p>Shares of pet healthcare company&nbsp;<b>Zomedica</b>(NYSEAMERICAN:<b>ZOM</b>) have had an impressive turnaround this week. ZOM stock has gained an whopping 51.4% on the back of renewed retail trading interest in the stock.</p>\n<p>The gains come after the shares had lost a near equal amount in the three months ending Aug. 18. Yet despite this week’s pop, weak fundamentals, unimpressive top-line growth and supply-side issues limit the stock’s attractiveness.</p>\n<p>Zomedica’s flagship product is a&nbsp;diagnostics platform called Truforma, which enables veterinarians to detect animal pathologies. It essentially streamlines the decision-making process, enabling veterinarians to begin treating patients — primarily dogs and cats — sooner.</p>\n<p>The innovative platform launched in March this year but so far hasn’t gained as much traction as its shareholders would’ve hoped for. The novelty of the platform cannot be denied, though, and some catalysts could drive growth in the future. However, Zomedica is far from where it should be, and its bullish narrative is hardly convincing at this stage.</p>\n<p><b>ZOM Stock Sees Supply-Side Troubles</b></p>\n<p>CEO Robert Cohen highlighted the troubles in ramping up the commercial launch of Truforma in the second-quarter update. He associated the supply-side weaknesses with its partners. Its&nbsp;distribution partner,<b>Miller Veterinary Supply</b>&nbsp;was acquired by&nbsp;<b>Patterson Companies</b>&nbsp;recently. The unexpected sale of its key distributor has compelled the company to alter its sales strategy.</p>\n<p>It announced that it would be transitioning to a direct sales organization. Zomedica “believed have impacted its ability to market our products effectively, we will be accelerating that transition and the building of a direct sales organization.”</p>\n<p>Moreover, Cohen believes that the delays in completing its fT4 and ACTH assays have also impacted Truforma’s performance. He stated that “We expect that&nbsp;market adoption of Truforma will be challenging&nbsp;until our fT4 and ACTH assays are available for commercial release.”</p>\n<p><b>Making Little Progress</b></p>\n<p>One thing that is unequivocal at this point is Zomedica’s poor financial performance. In the second quarter, it reported&nbsp;just $15,693 in revenues. In the first quarter, its sales were at $14,124; therefore, it hasn’t made much progress. Moreover, it posted a healthy net loss of $4.7 million in the quarter, $700,000 more than the first quarter.</p>\n<p>Perhaps a bright spot of its financials is its strong cash position. Its cash balance&nbsp;was at $276 million, which has a lot to do with the sale of over 91 million shares this year. Hence, the increase in its cash till came at a heavy price to its shareholders.</p>\n<p>From a business standpoint, there are some positive developments which you should probably keep an eye on.</p>\n<p>It implemented a program that allows customers to receive Truforma instruments if they purchase assay cartridges. Additionally, the company has signed 41 placement agreements and installed 25 Truforma systems under this program. This move could prove to be instrumental for the company in expanding its product lineup.</p>\n<p>Zomedica must continue to add value for its customer base to ramp up top-line growth.</p>\n<p><b>Final Word On ZOM Stock</b></p>\n<p>It’s been quite an eventful year for Zomedica and ZOM stock. After skyrocketing earlier in the year, ZOM stock has come crashing down, as its underlying business has failed to impress investors. Zomedica has failed to ramp up sales of its Truforma platform, raising concerns about the product’s long-term growth runway.</p>\n<p>It does have some exciting developments on the cards, and the transition to a direct sales model pays dividends down the line. However, the transitory phase should take long before it proves fruitful for the manufacturer of the diagnostic. Moreover, the direct sales strategy could also backfire, requiring it to reestablish relationships with the original distributor or pursue new ones.</p>\n<p>Zomedica has a lot to prove at this stage before investors can consider ZOM stock as an attractive investment.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRisks Outweigh Rewards of a Move Into Zomedica Stock Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 20:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ...</p>\n\n<a href=\"https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZOM":"Zomedica Pharmaceuticals Corp."},"source_url":"https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144882928","content_text":"ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ZOM stock has gained an whopping 51.4% on the back of renewed retail trading interest in the stock.\nThe gains come after the shares had lost a near equal amount in the three months ending Aug. 18. Yet despite this week’s pop, weak fundamentals, unimpressive top-line growth and supply-side issues limit the stock’s attractiveness.\nZomedica’s flagship product is a diagnostics platform called Truforma, which enables veterinarians to detect animal pathologies. It essentially streamlines the decision-making process, enabling veterinarians to begin treating patients — primarily dogs and cats — sooner.\nThe innovative platform launched in March this year but so far hasn’t gained as much traction as its shareholders would’ve hoped for. The novelty of the platform cannot be denied, though, and some catalysts could drive growth in the future. However, Zomedica is far from where it should be, and its bullish narrative is hardly convincing at this stage.\nZOM Stock Sees Supply-Side Troubles\nCEO Robert Cohen highlighted the troubles in ramping up the commercial launch of Truforma in the second-quarter update. He associated the supply-side weaknesses with its partners. Its distribution partner,Miller Veterinary Supply was acquired by Patterson Companies recently. The unexpected sale of its key distributor has compelled the company to alter its sales strategy.\nIt announced that it would be transitioning to a direct sales organization. Zomedica “believed have impacted its ability to market our products effectively, we will be accelerating that transition and the building of a direct sales organization.”\nMoreover, Cohen believes that the delays in completing its fT4 and ACTH assays have also impacted Truforma’s performance. He stated that “We expect that market adoption of Truforma will be challenging until our fT4 and ACTH assays are available for commercial release.”\nMaking Little Progress\nOne thing that is unequivocal at this point is Zomedica’s poor financial performance. In the second quarter, it reported just $15,693 in revenues. In the first quarter, its sales were at $14,124; therefore, it hasn’t made much progress. Moreover, it posted a healthy net loss of $4.7 million in the quarter, $700,000 more than the first quarter.\nPerhaps a bright spot of its financials is its strong cash position. Its cash balance was at $276 million, which has a lot to do with the sale of over 91 million shares this year. Hence, the increase in its cash till came at a heavy price to its shareholders.\nFrom a business standpoint, there are some positive developments which you should probably keep an eye on.\nIt implemented a program that allows customers to receive Truforma instruments if they purchase assay cartridges. Additionally, the company has signed 41 placement agreements and installed 25 Truforma systems under this program. This move could prove to be instrumental for the company in expanding its product lineup.\nZomedica must continue to add value for its customer base to ramp up top-line growth.\nFinal Word On ZOM Stock\nIt’s been quite an eventful year for Zomedica and ZOM stock. After skyrocketing earlier in the year, ZOM stock has come crashing down, as its underlying business has failed to impress investors. Zomedica has failed to ramp up sales of its Truforma platform, raising concerns about the product’s long-term growth runway.\nIt does have some exciting developments on the cards, and the transition to a direct sales model pays dividends down the line. However, the transitory phase should take long before it proves fruitful for the manufacturer of the diagnostic. Moreover, the direct sales strategy could also backfire, requiring it to reestablish relationships with the original distributor or pursue new ones.\nZomedica has a lot to prove at this stage before investors can consider ZOM stock as an attractive investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":819211655,"gmtCreate":1630072049677,"gmtModify":1704955526191,"author":{"id":"3586435391928672","authorId":"3586435391928672","name":"rachellll","avatar":"https://static.tigerbbs.com/7855a29f75174783f11b5102e8a7c8ba","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3586435391928672","authorIdStr":"3586435391928672"},"htmlText":"a","listText":"a","text":"a","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/819211655","repostId":1144882928,"repostType":4,"repost":{"id":"1144882928","pubTimestamp":1630068928,"share":"https://www.laohu8.com/m/news/1144882928?lang=&edition=full","pubTime":"2021-08-27 20:55","market":"us","language":"en","title":"Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1144882928","media":"InvestorPlace","summary":"ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares","content":"<p>ZOM stock investors won't get excited until the pet health disruptor improves top-line growth</p>\n<p>Shares of pet healthcare company&nbsp;<b>Zomedica</b>(NYSEAMERICAN:<b>ZOM</b>) have had an impressive turnaround this week. ZOM stock has gained an whopping 51.4% on the back of renewed retail trading interest in the stock.</p>\n<p>The gains come after the shares had lost a near equal amount in the three months ending Aug. 18. Yet despite this week’s pop, weak fundamentals, unimpressive top-line growth and supply-side issues limit the stock’s attractiveness.</p>\n<p>Zomedica’s flagship product is a&nbsp;diagnostics platform called Truforma, which enables veterinarians to detect animal pathologies. It essentially streamlines the decision-making process, enabling veterinarians to begin treating patients — primarily dogs and cats — sooner.</p>\n<p>The innovative platform launched in March this year but so far hasn’t gained as much traction as its shareholders would’ve hoped for. The novelty of the platform cannot be denied, though, and some catalysts could drive growth in the future. However, Zomedica is far from where it should be, and its bullish narrative is hardly convincing at this stage.</p>\n<p><b>ZOM Stock Sees Supply-Side Troubles</b></p>\n<p>CEO Robert Cohen highlighted the troubles in ramping up the commercial launch of Truforma in the second-quarter update. He associated the supply-side weaknesses with its partners. Its&nbsp;distribution partner,<b>Miller Veterinary Supply</b>&nbsp;was acquired by&nbsp;<b>Patterson Companies</b>&nbsp;recently. The unexpected sale of its key distributor has compelled the company to alter its sales strategy.</p>\n<p>It announced that it would be transitioning to a direct sales organization. Zomedica “believed have impacted its ability to market our products effectively, we will be accelerating that transition and the building of a direct sales organization.”</p>\n<p>Moreover, Cohen believes that the delays in completing its fT4 and ACTH assays have also impacted Truforma’s performance. He stated that “We expect that&nbsp;market adoption of Truforma will be challenging&nbsp;until our fT4 and ACTH assays are available for commercial release.”</p>\n<p><b>Making Little Progress</b></p>\n<p>One thing that is unequivocal at this point is Zomedica’s poor financial performance. In the second quarter, it reported&nbsp;just $15,693 in revenues. In the first quarter, its sales were at $14,124; therefore, it hasn’t made much progress. Moreover, it posted a healthy net loss of $4.7 million in the quarter, $700,000 more than the first quarter.</p>\n<p>Perhaps a bright spot of its financials is its strong cash position. Its cash balance&nbsp;was at $276 million, which has a lot to do with the sale of over 91 million shares this year. Hence, the increase in its cash till came at a heavy price to its shareholders.</p>\n<p>From a business standpoint, there are some positive developments which you should probably keep an eye on.</p>\n<p>It implemented a program that allows customers to receive Truforma instruments if they purchase assay cartridges. Additionally, the company has signed 41 placement agreements and installed 25 Truforma systems under this program. This move could prove to be instrumental for the company in expanding its product lineup.</p>\n<p>Zomedica must continue to add value for its customer base to ramp up top-line growth.</p>\n<p><b>Final Word On ZOM Stock</b></p>\n<p>It’s been quite an eventful year for Zomedica and ZOM stock. After skyrocketing earlier in the year, ZOM stock has come crashing down, as its underlying business has failed to impress investors. Zomedica has failed to ramp up sales of its Truforma platform, raising concerns about the product’s long-term growth runway.</p>\n<p>It does have some exciting developments on the cards, and the transition to a direct sales model pays dividends down the line. However, the transitory phase should take long before it proves fruitful for the manufacturer of the diagnostic. Moreover, the direct sales strategy could also backfire, requiring it to reestablish relationships with the original distributor or pursue new ones.</p>\n<p>Zomedica has a lot to prove at this stage before investors can consider ZOM stock as an attractive investment.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRisks Outweigh Rewards of a Move Into Zomedica Stock Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 20:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ...</p>\n\n<a href=\"https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZOM":"Zomedica Pharmaceuticals Corp."},"source_url":"https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144882928","content_text":"ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ZOM stock has gained an whopping 51.4% on the back of renewed retail trading interest in the stock.\nThe gains come after the shares had lost a near equal amount in the three months ending Aug. 18. Yet despite this week’s pop, weak fundamentals, unimpressive top-line growth and supply-side issues limit the stock’s attractiveness.\nZomedica’s flagship product is a diagnostics platform called Truforma, which enables veterinarians to detect animal pathologies. It essentially streamlines the decision-making process, enabling veterinarians to begin treating patients — primarily dogs and cats — sooner.\nThe innovative platform launched in March this year but so far hasn’t gained as much traction as its shareholders would’ve hoped for. The novelty of the platform cannot be denied, though, and some catalysts could drive growth in the future. However, Zomedica is far from where it should be, and its bullish narrative is hardly convincing at this stage.\nZOM Stock Sees Supply-Side Troubles\nCEO Robert Cohen highlighted the troubles in ramping up the commercial launch of Truforma in the second-quarter update. He associated the supply-side weaknesses with its partners. Its distribution partner,Miller Veterinary Supply was acquired by Patterson Companies recently. The unexpected sale of its key distributor has compelled the company to alter its sales strategy.\nIt announced that it would be transitioning to a direct sales organization. Zomedica “believed have impacted its ability to market our products effectively, we will be accelerating that transition and the building of a direct sales organization.”\nMoreover, Cohen believes that the delays in completing its fT4 and ACTH assays have also impacted Truforma’s performance. He stated that “We expect that market adoption of Truforma will be challenging until our fT4 and ACTH assays are available for commercial release.”\nMaking Little Progress\nOne thing that is unequivocal at this point is Zomedica’s poor financial performance. In the second quarter, it reported just $15,693 in revenues. In the first quarter, its sales were at $14,124; therefore, it hasn’t made much progress. Moreover, it posted a healthy net loss of $4.7 million in the quarter, $700,000 more than the first quarter.\nPerhaps a bright spot of its financials is its strong cash position. Its cash balance was at $276 million, which has a lot to do with the sale of over 91 million shares this year. Hence, the increase in its cash till came at a heavy price to its shareholders.\nFrom a business standpoint, there are some positive developments which you should probably keep an eye on.\nIt implemented a program that allows customers to receive Truforma instruments if they purchase assay cartridges. Additionally, the company has signed 41 placement agreements and installed 25 Truforma systems under this program. This move could prove to be instrumental for the company in expanding its product lineup.\nZomedica must continue to add value for its customer base to ramp up top-line growth.\nFinal Word On ZOM Stock\nIt’s been quite an eventful year for Zomedica and ZOM stock. After skyrocketing earlier in the year, ZOM stock has come crashing down, as its underlying business has failed to impress investors. Zomedica has failed to ramp up sales of its Truforma platform, raising concerns about the product’s long-term growth runway.\nIt does have some exciting developments on the cards, and the transition to a direct sales model pays dividends down the line. However, the transitory phase should take long before it proves fruitful for the manufacturer of the diagnostic. Moreover, the direct sales strategy could also backfire, requiring it to reestablish relationships with the original distributor or pursue new ones.\nZomedica has a lot to prove at this stage before investors can consider ZOM stock as an attractive investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5667610,"gmtCreate":1630072055041,"gmtModify":1631892588764,"authorId":3586435391928672,"author":{"id":3586435391928672,"idStr":"3586435391928672","authorId":3586435391928672,"name":"rachellll","avatar":"https://static.tigerbbs.com/7855a29f75174783f11b5102e8a7c8ba","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":819211655,"type":1,"supId":0,"prevId":0,"content":"a","text":"a","html":"a"}],"langContent":"EN"},{"id":819203002,"gmtCreate":1630070575906,"gmtModify":1704955481211,"author":{"id":"3584967080149000","authorId":"3584967080149000","name":"Jggggtjg","avatar":"https://static.tigerbbs.com/d44a6c7cca471293970e3a6ac785b580","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3584967080149000","authorIdStr":"3584967080149000"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/819203002","repostId":1144882928,"repostType":4,"repost":{"id":"1144882928","pubTimestamp":1630068928,"share":"https://www.laohu8.com/m/news/1144882928?lang=&edition=full","pubTime":"2021-08-27 20:55","market":"us","language":"en","title":"Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1144882928","media":"InvestorPlace","summary":"ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares","content":"<p>ZOM stock investors won't get excited until the pet health disruptor improves top-line growth</p>\n<p>Shares of pet healthcare company&nbsp;<b>Zomedica</b>(NYSEAMERICAN:<b>ZOM</b>) have had an impressive turnaround this week. ZOM stock has gained an whopping 51.4% on the back of renewed retail trading interest in the stock.</p>\n<p>The gains come after the shares had lost a near equal amount in the three months ending Aug. 18. Yet despite this week’s pop, weak fundamentals, unimpressive top-line growth and supply-side issues limit the stock’s attractiveness.</p>\n<p>Zomedica’s flagship product is a&nbsp;diagnostics platform called Truforma, which enables veterinarians to detect animal pathologies. It essentially streamlines the decision-making process, enabling veterinarians to begin treating patients — primarily dogs and cats — sooner.</p>\n<p>The innovative platform launched in March this year but so far hasn’t gained as much traction as its shareholders would’ve hoped for. The novelty of the platform cannot be denied, though, and some catalysts could drive growth in the future. However, Zomedica is far from where it should be, and its bullish narrative is hardly convincing at this stage.</p>\n<p><b>ZOM Stock Sees Supply-Side Troubles</b></p>\n<p>CEO Robert Cohen highlighted the troubles in ramping up the commercial launch of Truforma in the second-quarter update. He associated the supply-side weaknesses with its partners. Its&nbsp;distribution partner,<b>Miller Veterinary Supply</b>&nbsp;was acquired by&nbsp;<b>Patterson Companies</b>&nbsp;recently. The unexpected sale of its key distributor has compelled the company to alter its sales strategy.</p>\n<p>It announced that it would be transitioning to a direct sales organization. Zomedica “believed have impacted its ability to market our products effectively, we will be accelerating that transition and the building of a direct sales organization.”</p>\n<p>Moreover, Cohen believes that the delays in completing its fT4 and ACTH assays have also impacted Truforma’s performance. He stated that “We expect that&nbsp;market adoption of Truforma will be challenging&nbsp;until our fT4 and ACTH assays are available for commercial release.”</p>\n<p><b>Making Little Progress</b></p>\n<p>One thing that is unequivocal at this point is Zomedica’s poor financial performance. In the second quarter, it reported&nbsp;just $15,693 in revenues. In the first quarter, its sales were at $14,124; therefore, it hasn’t made much progress. Moreover, it posted a healthy net loss of $4.7 million in the quarter, $700,000 more than the first quarter.</p>\n<p>Perhaps a bright spot of its financials is its strong cash position. Its cash balance&nbsp;was at $276 million, which has a lot to do with the sale of over 91 million shares this year. Hence, the increase in its cash till came at a heavy price to its shareholders.</p>\n<p>From a business standpoint, there are some positive developments which you should probably keep an eye on.</p>\n<p>It implemented a program that allows customers to receive Truforma instruments if they purchase assay cartridges. Additionally, the company has signed 41 placement agreements and installed 25 Truforma systems under this program. This move could prove to be instrumental for the company in expanding its product lineup.</p>\n<p>Zomedica must continue to add value for its customer base to ramp up top-line growth.</p>\n<p><b>Final Word On ZOM Stock</b></p>\n<p>It’s been quite an eventful year for Zomedica and ZOM stock. After skyrocketing earlier in the year, ZOM stock has come crashing down, as its underlying business has failed to impress investors. Zomedica has failed to ramp up sales of its Truforma platform, raising concerns about the product’s long-term growth runway.</p>\n<p>It does have some exciting developments on the cards, and the transition to a direct sales model pays dividends down the line. However, the transitory phase should take long before it proves fruitful for the manufacturer of the diagnostic. Moreover, the direct sales strategy could also backfire, requiring it to reestablish relationships with the original distributor or pursue new ones.</p>\n<p>Zomedica has a lot to prove at this stage before investors can consider ZOM stock as an attractive investment.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRisks Outweigh Rewards of a Move Into Zomedica Stock Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 20:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ...</p>\n\n<a href=\"https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZOM":"Zomedica Pharmaceuticals Corp."},"source_url":"https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144882928","content_text":"ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ZOM stock has gained an whopping 51.4% on the back of renewed retail trading interest in the stock.\nThe gains come after the shares had lost a near equal amount in the three months ending Aug. 18. Yet despite this week’s pop, weak fundamentals, unimpressive top-line growth and supply-side issues limit the stock’s attractiveness.\nZomedica’s flagship product is a diagnostics platform called Truforma, which enables veterinarians to detect animal pathologies. It essentially streamlines the decision-making process, enabling veterinarians to begin treating patients — primarily dogs and cats — sooner.\nThe innovative platform launched in March this year but so far hasn’t gained as much traction as its shareholders would’ve hoped for. The novelty of the platform cannot be denied, though, and some catalysts could drive growth in the future. However, Zomedica is far from where it should be, and its bullish narrative is hardly convincing at this stage.\nZOM Stock Sees Supply-Side Troubles\nCEO Robert Cohen highlighted the troubles in ramping up the commercial launch of Truforma in the second-quarter update. He associated the supply-side weaknesses with its partners. Its distribution partner,Miller Veterinary Supply was acquired by Patterson Companies recently. The unexpected sale of its key distributor has compelled the company to alter its sales strategy.\nIt announced that it would be transitioning to a direct sales organization. Zomedica “believed have impacted its ability to market our products effectively, we will be accelerating that transition and the building of a direct sales organization.”\nMoreover, Cohen believes that the delays in completing its fT4 and ACTH assays have also impacted Truforma’s performance. He stated that “We expect that market adoption of Truforma will be challenging until our fT4 and ACTH assays are available for commercial release.”\nMaking Little Progress\nOne thing that is unequivocal at this point is Zomedica’s poor financial performance. In the second quarter, it reported just $15,693 in revenues. In the first quarter, its sales were at $14,124; therefore, it hasn’t made much progress. Moreover, it posted a healthy net loss of $4.7 million in the quarter, $700,000 more than the first quarter.\nPerhaps a bright spot of its financials is its strong cash position. Its cash balance was at $276 million, which has a lot to do with the sale of over 91 million shares this year. Hence, the increase in its cash till came at a heavy price to its shareholders.\nFrom a business standpoint, there are some positive developments which you should probably keep an eye on.\nIt implemented a program that allows customers to receive Truforma instruments if they purchase assay cartridges. Additionally, the company has signed 41 placement agreements and installed 25 Truforma systems under this program. This move could prove to be instrumental for the company in expanding its product lineup.\nZomedica must continue to add value for its customer base to ramp up top-line growth.\nFinal Word On ZOM Stock\nIt’s been quite an eventful year for Zomedica and ZOM stock. After skyrocketing earlier in the year, ZOM stock has come crashing down, as its underlying business has failed to impress investors. Zomedica has failed to ramp up sales of its Truforma platform, raising concerns about the product’s long-term growth runway.\nIt does have some exciting developments on the cards, and the transition to a direct sales model pays dividends down the line. However, the transitory phase should take long before it proves fruitful for the manufacturer of the diagnostic. Moreover, the direct sales strategy could also backfire, requiring it to reestablish relationships with the original distributor or pursue new ones.\nZomedica has a lot to prove at this stage before investors can consider ZOM stock as an attractive investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":819209532,"gmtCreate":1630070552626,"gmtModify":1704955480692,"author":{"id":"3573767135380290","authorId":"3573767135380290","name":"晓MIIN","avatar":"https://static.tigerbbs.com/9e223a6a40d05afa03fb58b646e13cd1","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3573767135380290","authorIdStr":"3573767135380290"},"htmlText":"[微笑]&nbsp;","listText":"[微笑]&nbsp;","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/819209532","repostId":1144882928,"repostType":4,"repost":{"id":"1144882928","pubTimestamp":1630068928,"share":"https://www.laohu8.com/m/news/1144882928?lang=&edition=full","pubTime":"2021-08-27 20:55","market":"us","language":"en","title":"Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1144882928","media":"InvestorPlace","summary":"ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares","content":"<p>ZOM stock investors won't get excited until the pet health disruptor improves top-line growth</p>\n<p>Shares of pet healthcare company&nbsp;<b>Zomedica</b>(NYSEAMERICAN:<b>ZOM</b>) have had an impressive turnaround this week. ZOM stock has gained an whopping 51.4% on the back of renewed retail trading interest in the stock.</p>\n<p>The gains come after the shares had lost a near equal amount in the three months ending Aug. 18. Yet despite this week’s pop, weak fundamentals, unimpressive top-line growth and supply-side issues limit the stock’s attractiveness.</p>\n<p>Zomedica’s flagship product is a&nbsp;diagnostics platform called Truforma, which enables veterinarians to detect animal pathologies. It essentially streamlines the decision-making process, enabling veterinarians to begin treating patients — primarily dogs and cats — sooner.</p>\n<p>The innovative platform launched in March this year but so far hasn’t gained as much traction as its shareholders would’ve hoped for. The novelty of the platform cannot be denied, though, and some catalysts could drive growth in the future. However, Zomedica is far from where it should be, and its bullish narrative is hardly convincing at this stage.</p>\n<p><b>ZOM Stock Sees Supply-Side Troubles</b></p>\n<p>CEO Robert Cohen highlighted the troubles in ramping up the commercial launch of Truforma in the second-quarter update. He associated the supply-side weaknesses with its partners. Its&nbsp;distribution partner,<b>Miller Veterinary Supply</b>&nbsp;was acquired by&nbsp;<b>Patterson Companies</b>&nbsp;recently. The unexpected sale of its key distributor has compelled the company to alter its sales strategy.</p>\n<p>It announced that it would be transitioning to a direct sales organization. Zomedica “believed have impacted its ability to market our products effectively, we will be accelerating that transition and the building of a direct sales organization.”</p>\n<p>Moreover, Cohen believes that the delays in completing its fT4 and ACTH assays have also impacted Truforma’s performance. He stated that “We expect that&nbsp;market adoption of Truforma will be challenging&nbsp;until our fT4 and ACTH assays are available for commercial release.”</p>\n<p><b>Making Little Progress</b></p>\n<p>One thing that is unequivocal at this point is Zomedica’s poor financial performance. In the second quarter, it reported&nbsp;just $15,693 in revenues. In the first quarter, its sales were at $14,124; therefore, it hasn’t made much progress. Moreover, it posted a healthy net loss of $4.7 million in the quarter, $700,000 more than the first quarter.</p>\n<p>Perhaps a bright spot of its financials is its strong cash position. Its cash balance&nbsp;was at $276 million, which has a lot to do with the sale of over 91 million shares this year. Hence, the increase in its cash till came at a heavy price to its shareholders.</p>\n<p>From a business standpoint, there are some positive developments which you should probably keep an eye on.</p>\n<p>It implemented a program that allows customers to receive Truforma instruments if they purchase assay cartridges. Additionally, the company has signed 41 placement agreements and installed 25 Truforma systems under this program. This move could prove to be instrumental for the company in expanding its product lineup.</p>\n<p>Zomedica must continue to add value for its customer base to ramp up top-line growth.</p>\n<p><b>Final Word On ZOM Stock</b></p>\n<p>It’s been quite an eventful year for Zomedica and ZOM stock. After skyrocketing earlier in the year, ZOM stock has come crashing down, as its underlying business has failed to impress investors. Zomedica has failed to ramp up sales of its Truforma platform, raising concerns about the product’s long-term growth runway.</p>\n<p>It does have some exciting developments on the cards, and the transition to a direct sales model pays dividends down the line. However, the transitory phase should take long before it proves fruitful for the manufacturer of the diagnostic. Moreover, the direct sales strategy could also backfire, requiring it to reestablish relationships with the original distributor or pursue new ones.</p>\n<p>Zomedica has a lot to prove at this stage before investors can consider ZOM stock as an attractive investment.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRisks Outweigh Rewards of a Move Into Zomedica Stock Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 20:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ...</p>\n\n<a href=\"https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZOM":"Zomedica Pharmaceuticals Corp."},"source_url":"https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144882928","content_text":"ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ZOM stock has gained an whopping 51.4% on the back of renewed retail trading interest in the stock.\nThe gains come after the shares had lost a near equal amount in the three months ending Aug. 18. Yet despite this week’s pop, weak fundamentals, unimpressive top-line growth and supply-side issues limit the stock’s attractiveness.\nZomedica’s flagship product is a diagnostics platform called Truforma, which enables veterinarians to detect animal pathologies. It essentially streamlines the decision-making process, enabling veterinarians to begin treating patients — primarily dogs and cats — sooner.\nThe innovative platform launched in March this year but so far hasn’t gained as much traction as its shareholders would’ve hoped for. The novelty of the platform cannot be denied, though, and some catalysts could drive growth in the future. However, Zomedica is far from where it should be, and its bullish narrative is hardly convincing at this stage.\nZOM Stock Sees Supply-Side Troubles\nCEO Robert Cohen highlighted the troubles in ramping up the commercial launch of Truforma in the second-quarter update. He associated the supply-side weaknesses with its partners. Its distribution partner,Miller Veterinary Supply was acquired by Patterson Companies recently. The unexpected sale of its key distributor has compelled the company to alter its sales strategy.\nIt announced that it would be transitioning to a direct sales organization. Zomedica “believed have impacted its ability to market our products effectively, we will be accelerating that transition and the building of a direct sales organization.”\nMoreover, Cohen believes that the delays in completing its fT4 and ACTH assays have also impacted Truforma’s performance. He stated that “We expect that market adoption of Truforma will be challenging until our fT4 and ACTH assays are available for commercial release.”\nMaking Little Progress\nOne thing that is unequivocal at this point is Zomedica’s poor financial performance. In the second quarter, it reported just $15,693 in revenues. In the first quarter, its sales were at $14,124; therefore, it hasn’t made much progress. Moreover, it posted a healthy net loss of $4.7 million in the quarter, $700,000 more than the first quarter.\nPerhaps a bright spot of its financials is its strong cash position. Its cash balance was at $276 million, which has a lot to do with the sale of over 91 million shares this year. Hence, the increase in its cash till came at a heavy price to its shareholders.\nFrom a business standpoint, there are some positive developments which you should probably keep an eye on.\nIt implemented a program that allows customers to receive Truforma instruments if they purchase assay cartridges. Additionally, the company has signed 41 placement agreements and installed 25 Truforma systems under this program. This move could prove to be instrumental for the company in expanding its product lineup.\nZomedica must continue to add value for its customer base to ramp up top-line growth.\nFinal Word On ZOM Stock\nIt’s been quite an eventful year for Zomedica and ZOM stock. After skyrocketing earlier in the year, ZOM stock has come crashing down, as its underlying business has failed to impress investors. Zomedica has failed to ramp up sales of its Truforma platform, raising concerns about the product’s long-term growth runway.\nIt does have some exciting developments on the cards, and the transition to a direct sales model pays dividends down the line. However, the transitory phase should take long before it proves fruitful for the manufacturer of the diagnostic. Moreover, the direct sales strategy could also backfire, requiring it to reestablish relationships with the original distributor or pursue new ones.\nZomedica has a lot to prove at this stage before investors can consider ZOM stock as an attractive investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":819209948,"gmtCreate":1630070531484,"gmtModify":1704955479999,"author":{"id":"3576662504844996","authorId":"3576662504844996","name":"Ice1234","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576662504844996","authorIdStr":"3576662504844996"},"htmlText":"[强]&nbsp;","listText":"[强]&nbsp;","text":"[强]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/819209948","repostId":1144882928,"repostType":4,"repost":{"id":"1144882928","pubTimestamp":1630068928,"share":"https://www.laohu8.com/m/news/1144882928?lang=&edition=full","pubTime":"2021-08-27 20:55","market":"us","language":"en","title":"Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1144882928","media":"InvestorPlace","summary":"ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares","content":"<p>ZOM stock investors won't get excited until the pet health disruptor improves top-line growth</p>\n<p>Shares of pet healthcare company&nbsp;<b>Zomedica</b>(NYSEAMERICAN:<b>ZOM</b>) have had an impressive turnaround this week. ZOM stock has gained an whopping 51.4% on the back of renewed retail trading interest in the stock.</p>\n<p>The gains come after the shares had lost a near equal amount in the three months ending Aug. 18. Yet despite this week’s pop, weak fundamentals, unimpressive top-line growth and supply-side issues limit the stock’s attractiveness.</p>\n<p>Zomedica’s flagship product is a&nbsp;diagnostics platform called Truforma, which enables veterinarians to detect animal pathologies. It essentially streamlines the decision-making process, enabling veterinarians to begin treating patients — primarily dogs and cats — sooner.</p>\n<p>The innovative platform launched in March this year but so far hasn’t gained as much traction as its shareholders would’ve hoped for. The novelty of the platform cannot be denied, though, and some catalysts could drive growth in the future. However, Zomedica is far from where it should be, and its bullish narrative is hardly convincing at this stage.</p>\n<p><b>ZOM Stock Sees Supply-Side Troubles</b></p>\n<p>CEO Robert Cohen highlighted the troubles in ramping up the commercial launch of Truforma in the second-quarter update. He associated the supply-side weaknesses with its partners. Its&nbsp;distribution partner,<b>Miller Veterinary Supply</b>&nbsp;was acquired by&nbsp;<b>Patterson Companies</b>&nbsp;recently. The unexpected sale of its key distributor has compelled the company to alter its sales strategy.</p>\n<p>It announced that it would be transitioning to a direct sales organization. Zomedica “believed have impacted its ability to market our products effectively, we will be accelerating that transition and the building of a direct sales organization.”</p>\n<p>Moreover, Cohen believes that the delays in completing its fT4 and ACTH assays have also impacted Truforma’s performance. He stated that “We expect that&nbsp;market adoption of Truforma will be challenging&nbsp;until our fT4 and ACTH assays are available for commercial release.”</p>\n<p><b>Making Little Progress</b></p>\n<p>One thing that is unequivocal at this point is Zomedica’s poor financial performance. In the second quarter, it reported&nbsp;just $15,693 in revenues. In the first quarter, its sales were at $14,124; therefore, it hasn’t made much progress. Moreover, it posted a healthy net loss of $4.7 million in the quarter, $700,000 more than the first quarter.</p>\n<p>Perhaps a bright spot of its financials is its strong cash position. Its cash balance&nbsp;was at $276 million, which has a lot to do with the sale of over 91 million shares this year. Hence, the increase in its cash till came at a heavy price to its shareholders.</p>\n<p>From a business standpoint, there are some positive developments which you should probably keep an eye on.</p>\n<p>It implemented a program that allows customers to receive Truforma instruments if they purchase assay cartridges. Additionally, the company has signed 41 placement agreements and installed 25 Truforma systems under this program. This move could prove to be instrumental for the company in expanding its product lineup.</p>\n<p>Zomedica must continue to add value for its customer base to ramp up top-line growth.</p>\n<p><b>Final Word On ZOM Stock</b></p>\n<p>It’s been quite an eventful year for Zomedica and ZOM stock. After skyrocketing earlier in the year, ZOM stock has come crashing down, as its underlying business has failed to impress investors. Zomedica has failed to ramp up sales of its Truforma platform, raising concerns about the product’s long-term growth runway.</p>\n<p>It does have some exciting developments on the cards, and the transition to a direct sales model pays dividends down the line. However, the transitory phase should take long before it proves fruitful for the manufacturer of the diagnostic. Moreover, the direct sales strategy could also backfire, requiring it to reestablish relationships with the original distributor or pursue new ones.</p>\n<p>Zomedica has a lot to prove at this stage before investors can consider ZOM stock as an attractive investment.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRisks Outweigh Rewards of a Move Into Zomedica Stock Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 20:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ...</p>\n\n<a href=\"https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZOM":"Zomedica Pharmaceuticals Corp."},"source_url":"https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144882928","content_text":"ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ZOM stock has gained an whopping 51.4% on the back of renewed retail trading interest in the stock.\nThe gains come after the shares had lost a near equal amount in the three months ending Aug. 18. Yet despite this week’s pop, weak fundamentals, unimpressive top-line growth and supply-side issues limit the stock’s attractiveness.\nZomedica’s flagship product is a diagnostics platform called Truforma, which enables veterinarians to detect animal pathologies. It essentially streamlines the decision-making process, enabling veterinarians to begin treating patients — primarily dogs and cats — sooner.\nThe innovative platform launched in March this year but so far hasn’t gained as much traction as its shareholders would’ve hoped for. The novelty of the platform cannot be denied, though, and some catalysts could drive growth in the future. However, Zomedica is far from where it should be, and its bullish narrative is hardly convincing at this stage.\nZOM Stock Sees Supply-Side Troubles\nCEO Robert Cohen highlighted the troubles in ramping up the commercial launch of Truforma in the second-quarter update. He associated the supply-side weaknesses with its partners. Its distribution partner,Miller Veterinary Supply was acquired by Patterson Companies recently. The unexpected sale of its key distributor has compelled the company to alter its sales strategy.\nIt announced that it would be transitioning to a direct sales organization. Zomedica “believed have impacted its ability to market our products effectively, we will be accelerating that transition and the building of a direct sales organization.”\nMoreover, Cohen believes that the delays in completing its fT4 and ACTH assays have also impacted Truforma’s performance. He stated that “We expect that market adoption of Truforma will be challenging until our fT4 and ACTH assays are available for commercial release.”\nMaking Little Progress\nOne thing that is unequivocal at this point is Zomedica’s poor financial performance. In the second quarter, it reported just $15,693 in revenues. In the first quarter, its sales were at $14,124; therefore, it hasn’t made much progress. Moreover, it posted a healthy net loss of $4.7 million in the quarter, $700,000 more than the first quarter.\nPerhaps a bright spot of its financials is its strong cash position. Its cash balance was at $276 million, which has a lot to do with the sale of over 91 million shares this year. Hence, the increase in its cash till came at a heavy price to its shareholders.\nFrom a business standpoint, there are some positive developments which you should probably keep an eye on.\nIt implemented a program that allows customers to receive Truforma instruments if they purchase assay cartridges. Additionally, the company has signed 41 placement agreements and installed 25 Truforma systems under this program. This move could prove to be instrumental for the company in expanding its product lineup.\nZomedica must continue to add value for its customer base to ramp up top-line growth.\nFinal Word On ZOM Stock\nIt’s been quite an eventful year for Zomedica and ZOM stock. After skyrocketing earlier in the year, ZOM stock has come crashing down, as its underlying business has failed to impress investors. Zomedica has failed to ramp up sales of its Truforma platform, raising concerns about the product’s long-term growth runway.\nIt does have some exciting developments on the cards, and the transition to a direct sales model pays dividends down the line. However, the transitory phase should take long before it proves fruitful for the manufacturer of the diagnostic. Moreover, the direct sales strategy could also backfire, requiring it to reestablish relationships with the original distributor or pursue new ones.\nZomedica has a lot to prove at this stage before investors can consider ZOM stock as an attractive investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":819677511,"gmtCreate":1630070404933,"gmtModify":1704955478093,"author":{"id":"3563319809929304","authorId":"3563319809929304","name":"dzgunners95","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3563319809929304","authorIdStr":"3563319809929304"},"htmlText":"Well done","listText":"Well done","text":"Well done","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/819677511","repostId":1144882928,"repostType":4,"repost":{"id":"1144882928","pubTimestamp":1630068928,"share":"https://www.laohu8.com/m/news/1144882928?lang=&edition=full","pubTime":"2021-08-27 20:55","market":"us","language":"en","title":"Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1144882928","media":"InvestorPlace","summary":"ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares","content":"<p>ZOM stock investors won't get excited until the pet health disruptor improves top-line growth</p>\n<p>Shares of pet healthcare company&nbsp;<b>Zomedica</b>(NYSEAMERICAN:<b>ZOM</b>) have had an impressive turnaround this week. ZOM stock has gained an whopping 51.4% on the back of renewed retail trading interest in the stock.</p>\n<p>The gains come after the shares had lost a near equal amount in the three months ending Aug. 18. Yet despite this week’s pop, weak fundamentals, unimpressive top-line growth and supply-side issues limit the stock’s attractiveness.</p>\n<p>Zomedica’s flagship product is a&nbsp;diagnostics platform called Truforma, which enables veterinarians to detect animal pathologies. It essentially streamlines the decision-making process, enabling veterinarians to begin treating patients — primarily dogs and cats — sooner.</p>\n<p>The innovative platform launched in March this year but so far hasn’t gained as much traction as its shareholders would’ve hoped for. The novelty of the platform cannot be denied, though, and some catalysts could drive growth in the future. However, Zomedica is far from where it should be, and its bullish narrative is hardly convincing at this stage.</p>\n<p><b>ZOM Stock Sees Supply-Side Troubles</b></p>\n<p>CEO Robert Cohen highlighted the troubles in ramping up the commercial launch of Truforma in the second-quarter update. He associated the supply-side weaknesses with its partners. Its&nbsp;distribution partner,<b>Miller Veterinary Supply</b>&nbsp;was acquired by&nbsp;<b>Patterson Companies</b>&nbsp;recently. The unexpected sale of its key distributor has compelled the company to alter its sales strategy.</p>\n<p>It announced that it would be transitioning to a direct sales organization. Zomedica “believed have impacted its ability to market our products effectively, we will be accelerating that transition and the building of a direct sales organization.”</p>\n<p>Moreover, Cohen believes that the delays in completing its fT4 and ACTH assays have also impacted Truforma’s performance. He stated that “We expect that&nbsp;market adoption of Truforma will be challenging&nbsp;until our fT4 and ACTH assays are available for commercial release.”</p>\n<p><b>Making Little Progress</b></p>\n<p>One thing that is unequivocal at this point is Zomedica’s poor financial performance. In the second quarter, it reported&nbsp;just $15,693 in revenues. In the first quarter, its sales were at $14,124; therefore, it hasn’t made much progress. Moreover, it posted a healthy net loss of $4.7 million in the quarter, $700,000 more than the first quarter.</p>\n<p>Perhaps a bright spot of its financials is its strong cash position. Its cash balance&nbsp;was at $276 million, which has a lot to do with the sale of over 91 million shares this year. Hence, the increase in its cash till came at a heavy price to its shareholders.</p>\n<p>From a business standpoint, there are some positive developments which you should probably keep an eye on.</p>\n<p>It implemented a program that allows customers to receive Truforma instruments if they purchase assay cartridges. Additionally, the company has signed 41 placement agreements and installed 25 Truforma systems under this program. This move could prove to be instrumental for the company in expanding its product lineup.</p>\n<p>Zomedica must continue to add value for its customer base to ramp up top-line growth.</p>\n<p><b>Final Word On ZOM Stock</b></p>\n<p>It’s been quite an eventful year for Zomedica and ZOM stock. After skyrocketing earlier in the year, ZOM stock has come crashing down, as its underlying business has failed to impress investors. Zomedica has failed to ramp up sales of its Truforma platform, raising concerns about the product’s long-term growth runway.</p>\n<p>It does have some exciting developments on the cards, and the transition to a direct sales model pays dividends down the line. However, the transitory phase should take long before it proves fruitful for the manufacturer of the diagnostic. Moreover, the direct sales strategy could also backfire, requiring it to reestablish relationships with the original distributor or pursue new ones.</p>\n<p>Zomedica has a lot to prove at this stage before investors can consider ZOM stock as an attractive investment.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRisks Outweigh Rewards of a Move Into Zomedica Stock Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 20:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ...</p>\n\n<a href=\"https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZOM":"Zomedica Pharmaceuticals Corp."},"source_url":"https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144882928","content_text":"ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ZOM stock has gained an whopping 51.4% on the back of renewed retail trading interest in the stock.\nThe gains come after the shares had lost a near equal amount in the three months ending Aug. 18. Yet despite this week’s pop, weak fundamentals, unimpressive top-line growth and supply-side issues limit the stock’s attractiveness.\nZomedica’s flagship product is a diagnostics platform called Truforma, which enables veterinarians to detect animal pathologies. It essentially streamlines the decision-making process, enabling veterinarians to begin treating patients — primarily dogs and cats — sooner.\nThe innovative platform launched in March this year but so far hasn’t gained as much traction as its shareholders would’ve hoped for. The novelty of the platform cannot be denied, though, and some catalysts could drive growth in the future. However, Zomedica is far from where it should be, and its bullish narrative is hardly convincing at this stage.\nZOM Stock Sees Supply-Side Troubles\nCEO Robert Cohen highlighted the troubles in ramping up the commercial launch of Truforma in the second-quarter update. He associated the supply-side weaknesses with its partners. Its distribution partner,Miller Veterinary Supply was acquired by Patterson Companies recently. The unexpected sale of its key distributor has compelled the company to alter its sales strategy.\nIt announced that it would be transitioning to a direct sales organization. Zomedica “believed have impacted its ability to market our products effectively, we will be accelerating that transition and the building of a direct sales organization.”\nMoreover, Cohen believes that the delays in completing its fT4 and ACTH assays have also impacted Truforma’s performance. He stated that “We expect that market adoption of Truforma will be challenging until our fT4 and ACTH assays are available for commercial release.”\nMaking Little Progress\nOne thing that is unequivocal at this point is Zomedica’s poor financial performance. In the second quarter, it reported just $15,693 in revenues. In the first quarter, its sales were at $14,124; therefore, it hasn’t made much progress. Moreover, it posted a healthy net loss of $4.7 million in the quarter, $700,000 more than the first quarter.\nPerhaps a bright spot of its financials is its strong cash position. Its cash balance was at $276 million, which has a lot to do with the sale of over 91 million shares this year. Hence, the increase in its cash till came at a heavy price to its shareholders.\nFrom a business standpoint, there are some positive developments which you should probably keep an eye on.\nIt implemented a program that allows customers to receive Truforma instruments if they purchase assay cartridges. Additionally, the company has signed 41 placement agreements and installed 25 Truforma systems under this program. This move could prove to be instrumental for the company in expanding its product lineup.\nZomedica must continue to add value for its customer base to ramp up top-line growth.\nFinal Word On ZOM Stock\nIt’s been quite an eventful year for Zomedica and ZOM stock. After skyrocketing earlier in the year, ZOM stock has come crashing down, as its underlying business has failed to impress investors. Zomedica has failed to ramp up sales of its Truforma platform, raising concerns about the product’s long-term growth runway.\nIt does have some exciting developments on the cards, and the transition to a direct sales model pays dividends down the line. However, the transitory phase should take long before it proves fruitful for the manufacturer of the diagnostic. Moreover, the direct sales strategy could also backfire, requiring it to reestablish relationships with the original distributor or pursue new ones.\nZomedica has a lot to prove at this stage before investors can consider ZOM stock as an attractive investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":819671438,"gmtCreate":1630069840924,"gmtModify":1704955469255,"author":{"id":"4088599389256890","authorId":"4088599389256890","name":"Andersonkana","avatar":"https://static.tigerbbs.com/21e08c99709245ba5acdcf7245d9c40f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4088599389256890","authorIdStr":"4088599389256890"},"htmlText":"Good news","listText":"Good news","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/819671438","repostId":1144882928,"repostType":4,"repost":{"id":"1144882928","pubTimestamp":1630068928,"share":"https://www.laohu8.com/m/news/1144882928?lang=&edition=full","pubTime":"2021-08-27 20:55","market":"us","language":"en","title":"Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1144882928","media":"InvestorPlace","summary":"ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares","content":"<p>ZOM stock investors won't get excited until the pet health disruptor improves top-line growth</p>\n<p>Shares of pet healthcare company&nbsp;<b>Zomedica</b>(NYSEAMERICAN:<b>ZOM</b>) have had an impressive turnaround this week. ZOM stock has gained an whopping 51.4% on the back of renewed retail trading interest in the stock.</p>\n<p>The gains come after the shares had lost a near equal amount in the three months ending Aug. 18. Yet despite this week’s pop, weak fundamentals, unimpressive top-line growth and supply-side issues limit the stock’s attractiveness.</p>\n<p>Zomedica’s flagship product is a&nbsp;diagnostics platform called Truforma, which enables veterinarians to detect animal pathologies. It essentially streamlines the decision-making process, enabling veterinarians to begin treating patients — primarily dogs and cats — sooner.</p>\n<p>The innovative platform launched in March this year but so far hasn’t gained as much traction as its shareholders would’ve hoped for. The novelty of the platform cannot be denied, though, and some catalysts could drive growth in the future. However, Zomedica is far from where it should be, and its bullish narrative is hardly convincing at this stage.</p>\n<p><b>ZOM Stock Sees Supply-Side Troubles</b></p>\n<p>CEO Robert Cohen highlighted the troubles in ramping up the commercial launch of Truforma in the second-quarter update. He associated the supply-side weaknesses with its partners. Its&nbsp;distribution partner,<b>Miller Veterinary Supply</b>&nbsp;was acquired by&nbsp;<b>Patterson Companies</b>&nbsp;recently. The unexpected sale of its key distributor has compelled the company to alter its sales strategy.</p>\n<p>It announced that it would be transitioning to a direct sales organization. Zomedica “believed have impacted its ability to market our products effectively, we will be accelerating that transition and the building of a direct sales organization.”</p>\n<p>Moreover, Cohen believes that the delays in completing its fT4 and ACTH assays have also impacted Truforma’s performance. He stated that “We expect that&nbsp;market adoption of Truforma will be challenging&nbsp;until our fT4 and ACTH assays are available for commercial release.”</p>\n<p><b>Making Little Progress</b></p>\n<p>One thing that is unequivocal at this point is Zomedica’s poor financial performance. In the second quarter, it reported&nbsp;just $15,693 in revenues. In the first quarter, its sales were at $14,124; therefore, it hasn’t made much progress. Moreover, it posted a healthy net loss of $4.7 million in the quarter, $700,000 more than the first quarter.</p>\n<p>Perhaps a bright spot of its financials is its strong cash position. Its cash balance&nbsp;was at $276 million, which has a lot to do with the sale of over 91 million shares this year. Hence, the increase in its cash till came at a heavy price to its shareholders.</p>\n<p>From a business standpoint, there are some positive developments which you should probably keep an eye on.</p>\n<p>It implemented a program that allows customers to receive Truforma instruments if they purchase assay cartridges. Additionally, the company has signed 41 placement agreements and installed 25 Truforma systems under this program. This move could prove to be instrumental for the company in expanding its product lineup.</p>\n<p>Zomedica must continue to add value for its customer base to ramp up top-line growth.</p>\n<p><b>Final Word On ZOM Stock</b></p>\n<p>It’s been quite an eventful year for Zomedica and ZOM stock. After skyrocketing earlier in the year, ZOM stock has come crashing down, as its underlying business has failed to impress investors. Zomedica has failed to ramp up sales of its Truforma platform, raising concerns about the product’s long-term growth runway.</p>\n<p>It does have some exciting developments on the cards, and the transition to a direct sales model pays dividends down the line. However, the transitory phase should take long before it proves fruitful for the manufacturer of the diagnostic. Moreover, the direct sales strategy could also backfire, requiring it to reestablish relationships with the original distributor or pursue new ones.</p>\n<p>Zomedica has a lot to prove at this stage before investors can consider ZOM stock as an attractive investment.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRisks Outweigh Rewards of a Move Into Zomedica Stock Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 20:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ...</p>\n\n<a href=\"https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZOM":"Zomedica Pharmaceuticals Corp."},"source_url":"https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144882928","content_text":"ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ZOM stock has gained an whopping 51.4% on the back of renewed retail trading interest in the stock.\nThe gains come after the shares had lost a near equal amount in the three months ending Aug. 18. Yet despite this week’s pop, weak fundamentals, unimpressive top-line growth and supply-side issues limit the stock’s attractiveness.\nZomedica’s flagship product is a diagnostics platform called Truforma, which enables veterinarians to detect animal pathologies. It essentially streamlines the decision-making process, enabling veterinarians to begin treating patients — primarily dogs and cats — sooner.\nThe innovative platform launched in March this year but so far hasn’t gained as much traction as its shareholders would’ve hoped for. The novelty of the platform cannot be denied, though, and some catalysts could drive growth in the future. However, Zomedica is far from where it should be, and its bullish narrative is hardly convincing at this stage.\nZOM Stock Sees Supply-Side Troubles\nCEO Robert Cohen highlighted the troubles in ramping up the commercial launch of Truforma in the second-quarter update. He associated the supply-side weaknesses with its partners. Its distribution partner,Miller Veterinary Supply was acquired by Patterson Companies recently. The unexpected sale of its key distributor has compelled the company to alter its sales strategy.\nIt announced that it would be transitioning to a direct sales organization. Zomedica “believed have impacted its ability to market our products effectively, we will be accelerating that transition and the building of a direct sales organization.”\nMoreover, Cohen believes that the delays in completing its fT4 and ACTH assays have also impacted Truforma’s performance. He stated that “We expect that market adoption of Truforma will be challenging until our fT4 and ACTH assays are available for commercial release.”\nMaking Little Progress\nOne thing that is unequivocal at this point is Zomedica’s poor financial performance. In the second quarter, it reported just $15,693 in revenues. In the first quarter, its sales were at $14,124; therefore, it hasn’t made much progress. Moreover, it posted a healthy net loss of $4.7 million in the quarter, $700,000 more than the first quarter.\nPerhaps a bright spot of its financials is its strong cash position. Its cash balance was at $276 million, which has a lot to do with the sale of over 91 million shares this year. Hence, the increase in its cash till came at a heavy price to its shareholders.\nFrom a business standpoint, there are some positive developments which you should probably keep an eye on.\nIt implemented a program that allows customers to receive Truforma instruments if they purchase assay cartridges. Additionally, the company has signed 41 placement agreements and installed 25 Truforma systems under this program. This move could prove to be instrumental for the company in expanding its product lineup.\nZomedica must continue to add value for its customer base to ramp up top-line growth.\nFinal Word On ZOM Stock\nIt’s been quite an eventful year for Zomedica and ZOM stock. After skyrocketing earlier in the year, ZOM stock has come crashing down, as its underlying business has failed to impress investors. Zomedica has failed to ramp up sales of its Truforma platform, raising concerns about the product’s long-term growth runway.\nIt does have some exciting developments on the cards, and the transition to a direct sales model pays dividends down the line. However, the transitory phase should take long before it proves fruitful for the manufacturer of the diagnostic. Moreover, the direct sales strategy could also backfire, requiring it to reestablish relationships with the original distributor or pursue new ones.\nZomedica has a lot to prove at this stage before investors can consider ZOM stock as an attractive investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5667277,"gmtCreate":1630070393977,"gmtModify":1635137837593,"authorId":3563319809929304,"author":{"id":3563319809929304,"idStr":"3563319809929304","authorId":3563319809929304,"name":"dzgunners95","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":819671438,"type":1,"supId":0,"prevId":0,"content":"<u>cool</u>","text":"<u>cool</u>","html":"<u>cool</u>"}],"langContent":"EN"},{"id":819645828,"gmtCreate":1630069372464,"gmtModify":1704955460217,"author":{"id":"4087734129298080","authorId":"4087734129298080","name":"IronRoar","avatar":"https://static.tigerbbs.com/cf9c156b794329cc799b0ee28ca0b9b2","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4087734129298080","authorIdStr":"4087734129298080"},"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/819645828","repostId":1144882928,"repostType":4,"repost":{"id":"1144882928","pubTimestamp":1630068928,"share":"https://www.laohu8.com/m/news/1144882928?lang=&edition=full","pubTime":"2021-08-27 20:55","market":"us","language":"en","title":"Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1144882928","media":"InvestorPlace","summary":"ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares","content":"<p>ZOM stock investors won't get excited until the pet health disruptor improves top-line growth</p>\n<p>Shares of pet healthcare company&nbsp;<b>Zomedica</b>(NYSEAMERICAN:<b>ZOM</b>) have had an impressive turnaround this week. ZOM stock has gained an whopping 51.4% on the back of renewed retail trading interest in the stock.</p>\n<p>The gains come after the shares had lost a near equal amount in the three months ending Aug. 18. Yet despite this week’s pop, weak fundamentals, unimpressive top-line growth and supply-side issues limit the stock’s attractiveness.</p>\n<p>Zomedica’s flagship product is a&nbsp;diagnostics platform called Truforma, which enables veterinarians to detect animal pathologies. It essentially streamlines the decision-making process, enabling veterinarians to begin treating patients — primarily dogs and cats — sooner.</p>\n<p>The innovative platform launched in March this year but so far hasn’t gained as much traction as its shareholders would’ve hoped for. The novelty of the platform cannot be denied, though, and some catalysts could drive growth in the future. However, Zomedica is far from where it should be, and its bullish narrative is hardly convincing at this stage.</p>\n<p><b>ZOM Stock Sees Supply-Side Troubles</b></p>\n<p>CEO Robert Cohen highlighted the troubles in ramping up the commercial launch of Truforma in the second-quarter update. He associated the supply-side weaknesses with its partners. Its&nbsp;distribution partner,<b>Miller Veterinary Supply</b>&nbsp;was acquired by&nbsp;<b>Patterson Companies</b>&nbsp;recently. The unexpected sale of its key distributor has compelled the company to alter its sales strategy.</p>\n<p>It announced that it would be transitioning to a direct sales organization. Zomedica “believed have impacted its ability to market our products effectively, we will be accelerating that transition and the building of a direct sales organization.”</p>\n<p>Moreover, Cohen believes that the delays in completing its fT4 and ACTH assays have also impacted Truforma’s performance. He stated that “We expect that&nbsp;market adoption of Truforma will be challenging&nbsp;until our fT4 and ACTH assays are available for commercial release.”</p>\n<p><b>Making Little Progress</b></p>\n<p>One thing that is unequivocal at this point is Zomedica’s poor financial performance. In the second quarter, it reported&nbsp;just $15,693 in revenues. In the first quarter, its sales were at $14,124; therefore, it hasn’t made much progress. Moreover, it posted a healthy net loss of $4.7 million in the quarter, $700,000 more than the first quarter.</p>\n<p>Perhaps a bright spot of its financials is its strong cash position. Its cash balance&nbsp;was at $276 million, which has a lot to do with the sale of over 91 million shares this year. Hence, the increase in its cash till came at a heavy price to its shareholders.</p>\n<p>From a business standpoint, there are some positive developments which you should probably keep an eye on.</p>\n<p>It implemented a program that allows customers to receive Truforma instruments if they purchase assay cartridges. Additionally, the company has signed 41 placement agreements and installed 25 Truforma systems under this program. This move could prove to be instrumental for the company in expanding its product lineup.</p>\n<p>Zomedica must continue to add value for its customer base to ramp up top-line growth.</p>\n<p><b>Final Word On ZOM Stock</b></p>\n<p>It’s been quite an eventful year for Zomedica and ZOM stock. After skyrocketing earlier in the year, ZOM stock has come crashing down, as its underlying business has failed to impress investors. Zomedica has failed to ramp up sales of its Truforma platform, raising concerns about the product’s long-term growth runway.</p>\n<p>It does have some exciting developments on the cards, and the transition to a direct sales model pays dividends down the line. However, the transitory phase should take long before it proves fruitful for the manufacturer of the diagnostic. Moreover, the direct sales strategy could also backfire, requiring it to reestablish relationships with the original distributor or pursue new ones.</p>\n<p>Zomedica has a lot to prove at this stage before investors can consider ZOM stock as an attractive investment.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRisks Outweigh Rewards of a Move Into Zomedica Stock Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 20:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ...</p>\n\n<a href=\"https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZOM":"Zomedica Pharmaceuticals Corp."},"source_url":"https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144882928","content_text":"ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ZOM stock has gained an whopping 51.4% on the back of renewed retail trading interest in the stock.\nThe gains come after the shares had lost a near equal amount in the three months ending Aug. 18. Yet despite this week’s pop, weak fundamentals, unimpressive top-line growth and supply-side issues limit the stock’s attractiveness.\nZomedica’s flagship product is a diagnostics platform called Truforma, which enables veterinarians to detect animal pathologies. It essentially streamlines the decision-making process, enabling veterinarians to begin treating patients — primarily dogs and cats — sooner.\nThe innovative platform launched in March this year but so far hasn’t gained as much traction as its shareholders would’ve hoped for. The novelty of the platform cannot be denied, though, and some catalysts could drive growth in the future. However, Zomedica is far from where it should be, and its bullish narrative is hardly convincing at this stage.\nZOM Stock Sees Supply-Side Troubles\nCEO Robert Cohen highlighted the troubles in ramping up the commercial launch of Truforma in the second-quarter update. He associated the supply-side weaknesses with its partners. Its distribution partner,Miller Veterinary Supply was acquired by Patterson Companies recently. The unexpected sale of its key distributor has compelled the company to alter its sales strategy.\nIt announced that it would be transitioning to a direct sales organization. Zomedica “believed have impacted its ability to market our products effectively, we will be accelerating that transition and the building of a direct sales organization.”\nMoreover, Cohen believes that the delays in completing its fT4 and ACTH assays have also impacted Truforma’s performance. He stated that “We expect that market adoption of Truforma will be challenging until our fT4 and ACTH assays are available for commercial release.”\nMaking Little Progress\nOne thing that is unequivocal at this point is Zomedica’s poor financial performance. In the second quarter, it reported just $15,693 in revenues. In the first quarter, its sales were at $14,124; therefore, it hasn’t made much progress. Moreover, it posted a healthy net loss of $4.7 million in the quarter, $700,000 more than the first quarter.\nPerhaps a bright spot of its financials is its strong cash position. Its cash balance was at $276 million, which has a lot to do with the sale of over 91 million shares this year. Hence, the increase in its cash till came at a heavy price to its shareholders.\nFrom a business standpoint, there are some positive developments which you should probably keep an eye on.\nIt implemented a program that allows customers to receive Truforma instruments if they purchase assay cartridges. Additionally, the company has signed 41 placement agreements and installed 25 Truforma systems under this program. This move could prove to be instrumental for the company in expanding its product lineup.\nZomedica must continue to add value for its customer base to ramp up top-line growth.\nFinal Word On ZOM Stock\nIt’s been quite an eventful year for Zomedica and ZOM stock. After skyrocketing earlier in the year, ZOM stock has come crashing down, as its underlying business has failed to impress investors. Zomedica has failed to ramp up sales of its Truforma platform, raising concerns about the product’s long-term growth runway.\nIt does have some exciting developments on the cards, and the transition to a direct sales model pays dividends down the line. However, the transitory phase should take long before it proves fruitful for the manufacturer of the diagnostic. Moreover, the direct sales strategy could also backfire, requiring it to reestablish relationships with the original distributor or pursue new ones.\nZomedica has a lot to prove at this stage before investors can consider ZOM stock as an attractive investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5667146,"gmtCreate":1630069678571,"gmtModify":1631889072335,"authorId":3573875235773606,"author":{"id":3573875235773606,"idStr":"3573875235773606","authorId":3573875235773606,"name":"JiaJun87","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":819645828,"type":1,"supId":0,"prevId":0,"content":"[Cool][Cool][Cool]","text":"[Cool][Cool][Cool]","html":"[Cool][Cool][Cool]"}],"langContent":"EN"},{"id":819642675,"gmtCreate":1630069294097,"gmtModify":1704955458817,"author":{"id":"3578617841803194","authorId":"3578617841803194","name":"ngng","avatar":"https://static.tigerbbs.com/b909b3a42bcfbf3b1cbd8bf9ed13dc8a","vip":1,"crmLevel":8,"crmLevelSwitch":0,"idStr":"3578617841803194","authorIdStr":"3578617841803194"},"htmlText":"Daily","listText":"Daily","text":"Daily","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/819642675","repostId":1144882928,"repostType":4,"repost":{"id":"1144882928","pubTimestamp":1630068928,"share":"https://www.laohu8.com/m/news/1144882928?lang=&edition=full","pubTime":"2021-08-27 20:55","market":"us","language":"en","title":"Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1144882928","media":"InvestorPlace","summary":"ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares","content":"<p>ZOM stock investors won't get excited until the pet health disruptor improves top-line growth</p>\n<p>Shares of pet healthcare company&nbsp;<b>Zomedica</b>(NYSEAMERICAN:<b>ZOM</b>) have had an impressive turnaround this week. ZOM stock has gained an whopping 51.4% on the back of renewed retail trading interest in the stock.</p>\n<p>The gains come after the shares had lost a near equal amount in the three months ending Aug. 18. Yet despite this week’s pop, weak fundamentals, unimpressive top-line growth and supply-side issues limit the stock’s attractiveness.</p>\n<p>Zomedica’s flagship product is a&nbsp;diagnostics platform called Truforma, which enables veterinarians to detect animal pathologies. It essentially streamlines the decision-making process, enabling veterinarians to begin treating patients — primarily dogs and cats — sooner.</p>\n<p>The innovative platform launched in March this year but so far hasn’t gained as much traction as its shareholders would’ve hoped for. The novelty of the platform cannot be denied, though, and some catalysts could drive growth in the future. However, Zomedica is far from where it should be, and its bullish narrative is hardly convincing at this stage.</p>\n<p><b>ZOM Stock Sees Supply-Side Troubles</b></p>\n<p>CEO Robert Cohen highlighted the troubles in ramping up the commercial launch of Truforma in the second-quarter update. He associated the supply-side weaknesses with its partners. Its&nbsp;distribution partner,<b>Miller Veterinary Supply</b>&nbsp;was acquired by&nbsp;<b>Patterson Companies</b>&nbsp;recently. The unexpected sale of its key distributor has compelled the company to alter its sales strategy.</p>\n<p>It announced that it would be transitioning to a direct sales organization. Zomedica “believed have impacted its ability to market our products effectively, we will be accelerating that transition and the building of a direct sales organization.”</p>\n<p>Moreover, Cohen believes that the delays in completing its fT4 and ACTH assays have also impacted Truforma’s performance. He stated that “We expect that&nbsp;market adoption of Truforma will be challenging&nbsp;until our fT4 and ACTH assays are available for commercial release.”</p>\n<p><b>Making Little Progress</b></p>\n<p>One thing that is unequivocal at this point is Zomedica’s poor financial performance. In the second quarter, it reported&nbsp;just $15,693 in revenues. In the first quarter, its sales were at $14,124; therefore, it hasn’t made much progress. Moreover, it posted a healthy net loss of $4.7 million in the quarter, $700,000 more than the first quarter.</p>\n<p>Perhaps a bright spot of its financials is its strong cash position. Its cash balance&nbsp;was at $276 million, which has a lot to do with the sale of over 91 million shares this year. Hence, the increase in its cash till came at a heavy price to its shareholders.</p>\n<p>From a business standpoint, there are some positive developments which you should probably keep an eye on.</p>\n<p>It implemented a program that allows customers to receive Truforma instruments if they purchase assay cartridges. Additionally, the company has signed 41 placement agreements and installed 25 Truforma systems under this program. This move could prove to be instrumental for the company in expanding its product lineup.</p>\n<p>Zomedica must continue to add value for its customer base to ramp up top-line growth.</p>\n<p><b>Final Word On ZOM Stock</b></p>\n<p>It’s been quite an eventful year for Zomedica and ZOM stock. After skyrocketing earlier in the year, ZOM stock has come crashing down, as its underlying business has failed to impress investors. Zomedica has failed to ramp up sales of its Truforma platform, raising concerns about the product’s long-term growth runway.</p>\n<p>It does have some exciting developments on the cards, and the transition to a direct sales model pays dividends down the line. However, the transitory phase should take long before it proves fruitful for the manufacturer of the diagnostic. Moreover, the direct sales strategy could also backfire, requiring it to reestablish relationships with the original distributor or pursue new ones.</p>\n<p>Zomedica has a lot to prove at this stage before investors can consider ZOM stock as an attractive investment.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Risks Outweigh Rewards of a Move Into Zomedica Stock Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRisks Outweigh Rewards of a Move Into Zomedica Stock Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 20:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ...</p>\n\n<a href=\"https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZOM":"Zomedica Pharmaceuticals Corp."},"source_url":"https://investorplace.com/2021/08/risks-outweigh-the-rewards-in-investing-in-zom-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144882928","content_text":"ZOM stock investors won't get excited until the pet health disruptor improves top-line growth\nShares of pet healthcare company Zomedica(NYSEAMERICAN:ZOM) have had an impressive turnaround this week. ZOM stock has gained an whopping 51.4% on the back of renewed retail trading interest in the stock.\nThe gains come after the shares had lost a near equal amount in the three months ending Aug. 18. Yet despite this week’s pop, weak fundamentals, unimpressive top-line growth and supply-side issues limit the stock’s attractiveness.\nZomedica’s flagship product is a diagnostics platform called Truforma, which enables veterinarians to detect animal pathologies. It essentially streamlines the decision-making process, enabling veterinarians to begin treating patients — primarily dogs and cats — sooner.\nThe innovative platform launched in March this year but so far hasn’t gained as much traction as its shareholders would’ve hoped for. The novelty of the platform cannot be denied, though, and some catalysts could drive growth in the future. However, Zomedica is far from where it should be, and its bullish narrative is hardly convincing at this stage.\nZOM Stock Sees Supply-Side Troubles\nCEO Robert Cohen highlighted the troubles in ramping up the commercial launch of Truforma in the second-quarter update. He associated the supply-side weaknesses with its partners. Its distribution partner,Miller Veterinary Supply was acquired by Patterson Companies recently. The unexpected sale of its key distributor has compelled the company to alter its sales strategy.\nIt announced that it would be transitioning to a direct sales organization. Zomedica “believed have impacted its ability to market our products effectively, we will be accelerating that transition and the building of a direct sales organization.”\nMoreover, Cohen believes that the delays in completing its fT4 and ACTH assays have also impacted Truforma’s performance. He stated that “We expect that market adoption of Truforma will be challenging until our fT4 and ACTH assays are available for commercial release.”\nMaking Little Progress\nOne thing that is unequivocal at this point is Zomedica’s poor financial performance. In the second quarter, it reported just $15,693 in revenues. In the first quarter, its sales were at $14,124; therefore, it hasn’t made much progress. Moreover, it posted a healthy net loss of $4.7 million in the quarter, $700,000 more than the first quarter.\nPerhaps a bright spot of its financials is its strong cash position. Its cash balance was at $276 million, which has a lot to do with the sale of over 91 million shares this year. Hence, the increase in its cash till came at a heavy price to its shareholders.\nFrom a business standpoint, there are some positive developments which you should probably keep an eye on.\nIt implemented a program that allows customers to receive Truforma instruments if they purchase assay cartridges. Additionally, the company has signed 41 placement agreements and installed 25 Truforma systems under this program. This move could prove to be instrumental for the company in expanding its product lineup.\nZomedica must continue to add value for its customer base to ramp up top-line growth.\nFinal Word On ZOM Stock\nIt’s been quite an eventful year for Zomedica and ZOM stock. After skyrocketing earlier in the year, ZOM stock has come crashing down, as its underlying business has failed to impress investors. Zomedica has failed to ramp up sales of its Truforma platform, raising concerns about the product’s long-term growth runway.\nIt does have some exciting developments on the cards, and the transition to a direct sales model pays dividends down the line. However, the transitory phase should take long before it proves fruitful for the manufacturer of the diagnostic. Moreover, the direct sales strategy could also backfire, requiring it to reestablish relationships with the original distributor or pursue new ones.\nZomedica has a lot to prove at this stage before investors can consider ZOM stock as an attractive investment.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":40,"commentSize":9,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}